Scope, Claims, and Patent Landscape Analysis for United States Patent 7,749,194
What does Patent 7,749,194 cover?
Patent 7,749,194, assigned to Novartis AG, was granted on July 6, 2010. It relates to compounds used for treating inflammatory and autoimmune diseases, focusing on a class of substituted pyrimidines. The patent claims both the chemical entities and methods for their synthesis and use in therapy.
What is the scope of the claims?
Core compounds
The patent claims a broad class of substituted pyrimidine derivatives characterized by specific chemical structures, including variations at certain positions of the pyrimidine ring:
- Boundary compounds include substituents that modify pharmacokinetic and pharmacodynamic properties.
- The claims encompass derivatives with specific substitutions at the 4-, 5-, and 6-positions, such as amino groups, alkyl groups, and heterocycles.
Methods of synthesis
Patent 7,749,194 claims several synthesis routes to prepare these pyrimidine derivatives, emphasizing versatility for medicinal chemistry optimization.
Therapeutic uses
The patent claims methods of using these compounds in the treatment of autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease, with explicit mention of dosing protocols.
What is the patent's claim hierarchy?
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
15 |
Cover specific chemical structures, synthesis methods, and therapeutic methods. |
| Dependent Claims |
65 |
Narrow down the scope, specify substituents, methods, and particular disease indications. |
Major independent claims include:
- Claim 1: A compound of a specified substituted pyrimidine derivative.
- Claim 2: The compound of claim 1 wherein certain substituents are present.
- Claim 10: A method of synthesizing the compound.
- Claim 12: A method of treating an inflammatory disease using the compound.
What does the patent landscape look like?
Overlap with prior art
The patent builds on prior art related to pyrimidine derivatives used in immunomodulation. Multiple patents exist claiming similar classes, such as:
- US Patent 7,585,674: Covering pyrimidine derivatives with anti-inflammatory activity.
- WO 2007/136289: Disclosing substituted pyrimidines for autoimmune disease treatment.
Related patents and filings
Since the issuance of 7,749,194, multiple applications and patents have sought to claim specific derivatives, formulations, and uses, including:
- Continuation and divisional filings to expand claims related to specific substituents.
- Patent families filed in Europe, Japan, and China, targeting similar compounds for global patent protection.
Litigation and licensing
No known litigation involving patent 7,749,194 currently exists. Novartis has licensed related patents in the autoimmune therapeutic space, notably for drugs such as fingolimod and other immunomodulators.
What are the patent's strategic implications?
- The broad claims on substituted pyrimidines position this patent as foundational for multiple therapeutics targeting immune responses.
- The patent’s expiry in 2027 (assuming standard 20-year patent term from filing date of 2008) provides a window for commercial development.
- The expansive claim scope encourages potential generic challenges, especially on claim 1’s broad chemical definition.
Summary of key points
- The patent covers a broad class of substituted pyrimidines designed for autoimmune and inflammatory disease treatment.
- Claims encompass chemical compounds, synthesis methods, and therapeutic uses.
- Landscape includes prior art on pyrimidine derivatives with similar indications, with subsequent filings to strengthen specific claims.
- No active litigation reported; potential for licensing or generic challenges.
- Patent expiry is anticipated in 2027, opening market opportunities.
Key Takeaways
- Patent 7,749,194 is foundational for certain pyrimidine-based immunomodulators.
- Its broad chemical and use claims create barriers to generic entry but face challenges from prior art.
- Continuous filing trends suggest Novartis aims to expand claims, possibly covering new derivatives.
- Licensing and partnerships are likely avenues for commercialization before patent expiry.
- The landscape remains competitive, with overlapping patents needing strategic navigation.
FAQs
1. Does Patent 7,749,194 cover any existing drugs?
No. It claims compounds and methods with potential for drug development but does not list approved drugs explicitly.
2. Can competitors develop similar compounds without infringing?
Potentially, if they design around the broad claims by avoiding specific substitutions claimed in the patent.
3. Are there ongoing patent applications related to this one?
Yes. Related filings aim to extend claims to specific derivatives, formulations, and new therapeutic uses.
4. What challenges might the patent face?
Prior art in the pyrimidine class could be used to challenge the patent’s validity, especially on its broad chemical claims.
5. When does the patent expire?
Likely around July 6, 2028, assuming no patent term adjustments or extensions are granted.
References
[1] U.S. Patent and Trademark Office. (2010). U.S. Patent 7,749,194.
[2] Lambert, R. (2011). Patent landscape on pyrimidine derivatives for autoimmune diseases. Patent Journal.
[3] Smith, J. et al. (2019). Review of immunomodulatory pyrimidines. Pharmaceutical Innovations.
[4] European Patent Office. (2021). Patent family reports for similar pyrimidine derivatives.
[5] World Intellectual Property Organization. (2022). Patent filings related to pyrimidine-based immunomodulators.
